BioSpace News Archive

Biotech Beach

Oncotelic Therapeutics, Inc. Awarded Top Cancer Immunotherapy Solutions Provider 2023

Oncotelic Therapeutics, Inc (OTCQB:OTLC) (“Oncotelic”, the “Company” or “We” or “Our”), announced today it was featured in Life Sciences Review, Cancer Immunology Edition and has been awarded a Top Cancer Immunotherapy Solutions Provider 2023 with other aluminous organizations.

August 25, 2023
·
6 min read
Novocure to Participate in Upcoming September 2023 Investor Conferences

Novocure announced that management will participate in two upcoming investor conferences.

August 25, 2023
·
3 min read
Drug Development

Nura Bio Initiates Phase I Clinical Trial for its Oral, Brain-Penetrant SARM1 Inhibitor, NB-4746

Nura Bio, Inc. (Nura Bio), a biopharmaceutical company developing neuroprotective, small molecule therapies for the treatment of debilitating neurological diseases, today announced the initiation of the Phase 1 clinical trial of its SARM1 inhibitor, NB-4746.

August 25, 2023
·
2 min read
Medtronic receives CE Mark approval for Inceptiv™ spinal cord stimulator with closed-loop sensing to treat chronic pain

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, has received CE (Conformité Européenne) Mark approval for its Inceptiv™ closed-loop rechargeable spinal cord stimulator (SCS).

August 25, 2023
·
4 min read
Business

Henlius 2023 H1 Results: Achieved record profits and RMB2.5 billion revenues, opening a new chapter of high-quality growth

Henlius announced its 2023 interim results. In the first half of 2023, Henlius reported a boost in operating profits of RMB240.0 million and revenues of RMB2.5005 billion, up by 93.9% YoY, driven by growth in core oncology products.

August 25, 2023
·
12 min read
Genetown

Astria Therapeutics to Present Patient Survey Data at Upcoming 2023 HAEi Regional EMEA Conference

Astria Therapeutics, Inc. (NASDAQ:ATXS) today announced that it will present information regarding patient preference for efficacy measures when starting on or switching to a new preventative therapy at the upcoming 2023 HAEi Regional EMEA Conference in Munich, Germany from September 1-3, 2023.

August 25, 2023
·
1 min read
Drug Development

First participant treated at the highest dose level in Clarity’s theranostic prostate cancer trial

Clarity Pharmaceuticals (ASX: CU6) (“Clarity”) is pleased to announce the dosing of the first participant at the highest dose level of 12GBq in the third cohort of its Phase I/II theranostic trial evaluating 67Cu SAR-bisPSMA in participants with metastatic, castrate-resistant prostate cancer (mCRPC).

August 25, 2023
·
5 min read
Business

Dr. Denise T. Dickinson M.D. Is First in Kentucky to Offer Nonsurgical Treatment for Common Skin Cancer

SkinCure Oncology announced its availability in Kentucky at an event at the Louisville office of Dr. Denise T. Dickinson M.D. It is the first medical practice in the state to offer this GentleCure™ treatment experience.

August 25, 2023
·
3 min read
Policy

SUSMED’s DTx Approved in Japan for the Treatment of Insomnia

SUSMED, Inc. (TOKYO:4263) announced that it obtained regulatory approval from the Ministry of Health, Labour and Welfare (the ”MHLW”) of SUSMED Med CBT-i® App for Insomnia (the ”product”).

August 25, 2023
·
4 min read
Policy

FDA Roundup: August 25, 2023

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

August 25, 2023
·
2 min read